GlaxoSmithKline - Latest News [Page 2]

GSK Consumer Healthcare statement on Ribena

Wednesday, 28 March 2007, 9:40 am | GlaxoSmithKline

27 March 2007: GlaxoSmithKline (GSK) Consumer Healthcare has accepted 15 representative charges brought by the Commerce Commission relating to a product claim and Vitamin C content information on Ribena. It is important to highlight that the Ribena range ... More >>

HIV medicine funding positive start to New Year

Thursday, 21 December 2006, 3:24 pm | GlaxoSmithKline

A new agreement between GlaxoSmithKline (GSK) and drug funding agency PHARMAC will lighten the pill load for HIV patients. A new once-daily HIV medication Kivexa™ (abacavir/lamivudine), which combines two antiretrovirals in one tablet, will be ... More >>

Asthma control in a puffer that counts

Wednesday, 26 July 2006, 10:54 am | GlaxoSmithKline

GlaxoSmithKline’s most successful asthma medicine, Seretide™, is now funded in New Zealand. Seretide (salmeterol/fluticasone) will be subsidised from 1st August. Seretide metered dose inhalers will be introduced containing a new dose counter that ... More >>

Human trials with two h5n1 vaccines

Wednesday, 31 May 2006, 4:00 pm | GlaxoSmithKline

May 24, 2006: GlaxoSmithKline (GSK) has announced the start of an international clinical trial programme to test two pandemic vaccines against the H5N1 strain of the avian influenza virus in humans. This dual approach reflects the company’s commitment to ... More >>

GlaxoSmithKline initiates human trial programme

Wednesday, 31 May 2006, 3:31 pm | GlaxoSmithKline

May 24, 2006: GlaxoSmithKline (GSK) has announced the start of an international clinical trial programme to test two pandemic vaccines against the H5N1 strain of the avian influenza virus in humans. This dual approach reflects the company’s commitment to ... More >>

Funding enables choice to people with Parkinson's

Friday, 28 October 2005, 10:40 am | GlaxoSmithKline

Auckland, 27th October 2005 – A new agreement between GlaxoSmithKline (GSK) and drug funding agency PHARMAC will allow people with Parkinson’s Disease funded access to Requip,™(ropinirole) which helps prevent the unpredictable movements caused by ... More >>

Green light for increased Serevent inhaler access

Thursday, 20 October 2005, 5:18 pm | GlaxoSmithKline

Stop putting up with asthma symptoms Green light for increased access to Serevent inhaler from 1st November More >>

Winning Low Allergy Garden Design at Ellerslie

Tuesday, 18 October 2005, 9:44 am | GlaxoSmithKline

News Release 17 October 2005 Winning Low Allergy Garden Design to be Constructed at Ellerslie Flower Show More >>

GSK Changes Will Not Impact Supply of Medicines

Tuesday, 17 May 2005, 12:24 am | GlaxoSmithKline

GSK Pharmaceuticals New Zealand has decided to change the way its business is structured in New Zealand. These proposed changes are the result of an in-depth analysis of the business environment in New Zealand. More >>

GSK price for Ventolin

Friday, 6 May 2005, 10:34 am | GlaxoSmithKline

Auckland, May 5th 2005 - Despite claims made by the Asthma & Respiratory Foundation (press release, 4th May 2005), GSK does not intend to change the price it charges for Ventolin to wholesalers after the 1st July when it will become available to New ... More >>

Ventolin to remain available after 1 July

Tuesday, 3 May 2005, 11:31 am | GlaxoSmithKline

Auckland, 2nd May 2005 – GlaxoSmithKline (GSK) will continue to make Ventolin™ (salbutamol) Metered Dose Inhaler (MDI) available to New Zealanders on prescription after July 1st as a Private Purchase Medicine (PPM) in order to ensure that New Zealanders continue ... More >>

Private Purchase Medicines Proving Popular Choice

Thursday, 17 February 2005, 9:26 am | GlaxoSmithKline

The demand for private purchase medicines is on the increase with GlaxoSmithKline (GSK) estimating that patients spent $60 to $70 million on all available private purchase medicines during 2004. More >>

HIV/Aids Medicines In Africa

Friday, 24 September 2004, 3:55 pm | GlaxoSmithKline

GSK has granted a voluntary licence under its patents to Cosmos Limited, a Kenyan pharmaceutical company, for the manufacture and sale of antiretrovirals (ARVs) containing zidovudine and/or lamivudine in the public and private sectors in Kenya and other ... More >>

Vigilance urged for reading medicine packaging

Friday, 9 July 2004, 12:02 am | GlaxoSmithKline

>From next week, New Zealand consumers will be able to buy ibuprofen-based products such as Nurofen(r) and Panafen IB(r) from supermarkets and on general sale around the country. More >>

Medicine could help relieve diabetes burden

Friday, 28 May 2004, 11:33 am | GlaxoSmithKline

GlaxoSmithKline says its treatment for type 2 diabetes, Avandia* (rosiglitazone maleate) could play a role in relieving the burgeoning burden that diabetes places on New Zealand's hospitals. More >>

GSK effort to eradicate deadly diseases

Wednesday, 26 May 2004, 4:49 pm | GlaxoSmithKline

GlaxoSmithKline Pharmaceuticals' (GSK) efforts to eradicate one of the world's most deadly diseases will be featured in a BBC World Television documentary to be broadcast to New Zealand Sky TV subscribers this Saturday (May 29). More >>

PHARMAC’s claims of success misleading

Friday, 14 May 2004, 5:16 pm | GlaxoSmithKline

New Zealand’s biggest supplier of asthma medications, GlaxoSmithKline is intrigued PHARMAC has come on board to help reduce doses of inhaled corticosteroid used in asthma. More >>

GSK & WHO unite to fight malaria

Thursday, 29 April 2004, 12:34 am | GlaxoSmithKline

Auckland, April 29, 2004 - GlaxoSmithKline (GSK), the World Health Organisation's Special Programme for Research and Training in Tropical Diseases (WHO-TDR) and the Medicines for Malaria Venture (MMV) today announced the signing of a collaborative ... More >>

New Sales and Marketing Director for GSK

Monday, 26 April 2004, 2:12 pm | GlaxoSmithKline

Rob brings to GSK a strong 20-year background in sales and marketing. He has extensive experience working with a variety of major global consumer brands in both the New Zealand and Asia food and beverage industries. More >>

Asthma reliever inhalers used one mln. times a day

Wednesday, 28 January 2004, 11:03 am | GlaxoSmithKline

Auckland, 28th January 2004 - Asthma patients are using their reliever inhaler more than twice as often as they should, and nationwide New Zealanders use one million reliever puffs a day. Over the last twelve months doctors have prescribed almost ... More >>

   

 
 
 
 
 

LATEST HEADLINES

  • PARLIAMENT
  • POLITICS
  • REGIONAL